Docoh
Loading...

26 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 3, 2021 NOTICE HEREBY IS GIVEN that a Special Meeting of Stockholders of Processa … of authorized shares of common stock from 30,000,000 shares to 50,000,000 shares; to approve an adjournment of the Special Meeting, if the Board of Directors
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
SEPTEMBER 1, 2021 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 3, 2021 NOTICE … HEREBY IS GIVEN that a Special Meeting of Stockholders of Processa Pharmaceuticals, Inc. will be held at 7380 Coca Cola Drive, Suite 106, Hanover, MD
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
stockholder, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
director has been elected to hold office until the next annual meeting of shareholders or special meeting in lieu of such annual meeting or until his
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
became an interested stockholder, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
is comprised of five members. Each director has been elected to hold office until the next annual meeting of shareholders or special meeting in lieu
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders, and not by written consent
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
at an annual or special meeting of stockholders by the holders of at least 66 2/3% of our voting stock not held by the stockholder engaging
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
to certain restrictions), or is approved at an annual or special meeting of stockholders by the holders of at least 66 2/3% of our voting stock not held … by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
voting stock (subject to certain restrictions), or is approved at an annual or special meeting of stockholders by the holders of at least 66 2/3% of our … by the Board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
restrictions), or is approved at an annual or special meeting of stockholders by the holders of at least 66 2/3% of our voting stock not held … an interested stockholder, the business combination is approved by the Board and authorized at an annual or special meeting of stockholders
S-1/A
EX-3.2
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of Directors shall determine the time and place, if any, of such special meeting. Upon determination of the time and place, if any, of the meeting … of these Bylaws. No business may be transacted at such special meeting otherwise than specified in the notice of meeting. (c) Nominations of persons
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders
S-1
PCSA Processa Pharmaceuticals Inc
13 Dec 19
IPO registration
5:32pm
, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent
DEF 14C
PCSA Processa Pharmaceuticals Inc
25 Nov 19
Information statement
2:29pm
and outstanding shares of Common Stock executed a written consent in lieu of a special meeting of stockholders, approving the following matter, which … stockholder by the execution a written consent in lieu of a special meeting of stockholders effective on November 7, 2019, had previously been approved
PRE 14C
PCSA Processa Pharmaceuticals Inc
12 Nov 19
Preliminary information
6:30am
and outstanding shares of Common Stock executed a written consent in lieu of a special meeting of stockholders, approving the following matter, which had … stockholder by the execution a written consent in lieu of a special meeting of stockholders effective on November , 2019, had previously been approved
424B3
PCSA Processa Pharmaceuticals Inc
9 Nov 18
Prospectus supplement
5:04pm
is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent